R
Rhonda K. Roby
Researcher at University of North Texas Health Science Center
Publications - 21
Citations - 1288
Rhonda K. Roby is an academic researcher from University of North Texas Health Science Center. The author has contributed to research in topics: Population & Mitochondrial DNA. The author has an hindex of 12, co-authored 21 publications receiving 1174 citations. Previous affiliations of Rhonda K. Roby include J. Craig Venter Institute & Armed Forces Institute of Pathology.
Papers
More filters
Journal ArticleDOI
Mitochondrial DNA sequence heteroplasmy in the Grand Duke of Russia Georgij Romanov establishes the authenticity of the remains of Tsar Nicholas II.
Pavel L. Ivanov,Mark J. Wadhams,Rhonda K. Roby,Mitchell M. Holland,Victor W. Weedn,Thomas J. Parsons +5 more
TL;DR: The skeletal remains of the Tsar's brother Georgij Romanov were analysed, at the request of the Russian Federation government, in order to gain further insight into the occurrence and segregation of heteroplasmic mtDNA variants in theTsar's maternal lineage.
Journal ArticleDOI
Developmental validation of a single-tube amplification of the 13 CODIS STR loci, D2S1338, D19S433, and amelogenin: the AmpFlSTR Identifiler PCR Amplification Kit
Patrick J. Collins,Lori K. Hennessy,Craig S. Leibelt,Rhonda K. Roby,Dennis J. Reeder,Paul A. Foxall +5 more
TL;DR: Results support the use of the AmpFlSTR Identifiler PCR Amplification Kit for human identity and parentage testing and are developed in accordance with the standards of the forensic community as defined by the DNA Advisory Board.
Journal ArticleDOI
Simultaneous quantification of mitochondrial DNA copy number and deletion ratio: A multiplex real-time PCR assay
TL;DR: A unique multiplex assay which simultaneously provides assessments of mtDNA copy number and the proportion of genomes with common large deletions by targeting two mitochondrial sites and one nuclear locus is described.
Journal ArticleDOI
Anti-cancer effects of novel flavonoid vicenin-2 as a single agent and in synergistic combination with docetaxel in prostate cancer.
Lokesh Dalasanur Nagaprashantha,Rit Vatsyayan,Jyotsana Singhal,Spence Fast,Rhonda K. Roby,Sanjay Awasthi,Sharad S. Singhal +6 more
TL;DR: Investigations collectively provide strong evidence that VCN-2 is effective against CaP progression along with indicating that VCn-2 and DTL co-administration is more effective than either of the single agents in androgen-independent prostate cancer.
Journal ArticleDOI
Identification of a D8S1179 primer binding site mutation and the validation of a primer designed to recover null alleles
Craig S. Leibelt,Bruce Budowle,Patrick J. Collins,Yasser Daoudi,Tamyra R. Moretti,Gary Nunn,Dennis J. Reeder,Rhonda K. Roby +7 more
TL;DR: A population study of Chamorros and Filipinos using short tandem repeat (STR) loci amplified with the AmpFlSTR Profiler Plus PCR amplification kit demonstrated an excess of observed homozygosity at the D8S1179 locus.